AdaptHealth Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 1, 2020, reports that AdaptHealth Corp. (the "Company") entered into a definitive Agreement and Plan of Merger to acquire AeroCare Holdings, Inc. ("AeroCare"). The Company is a Delaware corporation listed on The Nasdaq Stock Market LLC under the symbol "AHCO."
Key Financial Metrics and Transaction Structure
The filing details a material definitive agreement rather than periodic financial results. Key financial terms of the acquisition include:
- Total Consideration: Approximately $1.1 billion in cash plus equity.
- Equity Component: Shares of Class A Common Stock and a new series of "Series C Convertible Preferred Stock," representing the economic equivalent of 31,000,000 shares of Class A Common Stock on an as-converted basis.
- Financing: The cash portion is to be funded through cash on hand and incremental debt. The Company secured a debt commitment letter from Jefferies Finance LLC for up to $900 million in a senior secured term loan B facility and up to $450 million in a senior unsecured bridge facility.
- Termination Fee: The Company is obligated to pay a $60 million termination fee to AeroCare under specific breach or failure-to-close scenarios.
Material Changes and Governance
Upon closing, the Company's board of directors will increase by two members: Ted Lundberg (Class II director) and Stephen Griggs, the current CEO of AeroCare (Class I director). The AeroCare equityholders (Rights Holders) will have the right to designate one director and one non-voting observer to the board as long as they hold at least 35% of the combined Class A Common Stock and Series C Preferred Stock on an as-converted basis.
Outlook, Risks, and Contingencies
Closing Conditions: The transaction is expected to close in the first quarter of 2021, subject to regulatory approvals, the expiration of the Hart-Scott-Rodino waiting period, and the absence of legal orders barring the acquisition. A condition requires that no more than 3.5% of AeroCare shares demand appraisal rights.
Stockholder Approval: The Company must obtain stockholder approval to remove conversion restrictions on the Series C Preferred Stock. Voting agreements have been secured with holders representing greater than 50% of current voting power to support this approval.
Risks: The filing includes standard forward-looking statement disclaimers regarding the impact of the COVID-19 pandemic, competitive conditions in the healthcare sector, and potential judicial or administrative proceedings. The definitive debt documentation has not been finalized, and actual terms may differ from the commitment letter.
Investor Verification Checklist
- Verify the final terms of the debt financing with Jefferies Finance LLC, as definitive documentation is pending.
- Monitor the status of regulatory approvals and the Hart-Scott-Rodino waiting period expiration.
- Confirm the outcome of the stockholder vote required to approve the removal of conversion restrictions on the Series C Preferred Stock.
- Review the Certificate of Designations for the Series C Preferred Stock once filed with the Delaware Secretary of State.
- Assess the impact of the $60 million termination fee obligation on the Company's liquidity if the deal fails to close.